Sonelokimab

Phase 3Recruiting

0 views this week 0 watching⚡ Active

Interest: 41/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Hidradenitis Suppurativa

Conditions

Hidradenitis Suppurativa

Trial Timeline

Jun 27, 2025 → Jun 13, 2028

NCT ID

NCT07007637

About Sonelokimab

Sonelokimab is a phase 3 stage product being developed by MoonLake Immunotherapeutics for Hidradenitis Suppurativa. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07007637. Target conditions include Hidradenitis Suppurativa.

What happened to similar drugs?

1 of 20 similar drugs in Hidradenitis Suppurativa were approved

Approved (1) Terminated (0) Active (19)

✅Placebo + AdalimumabAbbVieApproved

🔄SonelokimabMoonLake ImmunotherapeuticsPhase 3

🔄Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3

🔄Lutikizumab + PlaceboAbbViePhase 3

🔄Upadacitinib + PlaceboAbbViePhase 3

🔄adalimumab + placeboAbbViePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07223138	Phase 3	Recruiting	Nov 13, 2025	Feb 4, 2028	Arthritis, Psoriatic
NCT07007637	Phase 3	Recruiting	Jun 27, 2025	Jun 13, 2028	Hidradenitis Suppurativa
NCT06768671	Phase 3	Recruiting	Dec 30, 2024	Mar 27, 2026	Hidradenitis Suppurativa

Competing Products

20 competing products in Hidradenitis Suppurativa

See all competitors

Product	Company	Stage	Hype Score
Sonelokimab	MoonLake Immunotherapeutics	Phase 3	41
Sonelokimab + Placebo	MoonLake Immunotherapeutics	Phase 3	38
Sonelokimab + Placebo	MoonLake Immunotherapeutics	Phase 3	38
Sonelokimab (M1095) + Adalimumab	MoonLake Immunotherapeutics	Phase 2	29
Eltrekibart + Placebo	Eli Lilly	Phase 2	39
Placebo + LY3041658	Eli Lilly	Phase 2	35
Placebo + Adalimumab	AbbVie	Approved	43
Lutikizumab + Placebo	AbbVie	Phase 3	47
Adalimumab	AbbVie	Pre-clinical	26
Upadacitinib + Placebo	AbbVie	Phase 3	47
adalimumab + placebo	AbbVie	Phase 3	40
Lutikizumab	AbbVie	Phase 2	42
adalimumab	AbbVie	Phase 3	40
Lutikizumab + Placebo	AbbVie	Phase 2	39
Risankizumab + Placebo for risankizumab	AbbVie	Phase 2	35
adalimumab	AbbVie	Phase 3	40
adalimumab + placebo	AbbVie	Phase 3	40
Upadacitinib + Placebo	AbbVie	Phase 2	35
MEDI8968 + Saline	AstraZeneca	Phase 2	27
Anifrolumab	AstraZeneca	Phase 2	39